Holen Sie sich die Stockscreener-App
2.3498
2.11%
-0.0202
Schlusskurs vom Vortag:
$2.37
Offen:
$2.36
24-Stunden-Volumen:
9,944
Relative Volume:
0.03
Marktkapitalisierung:
$153.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.84M
KGV:
-4.8459
EPS:
-0.4849
Netto-Cashflow:
$-23.88M
1W Leistung:
-5.31%
1M Leistung:
-18.02%
6M Leistung:
-55.64%
1J Leistung:
+63.38%
1-Tages-Spanne:
$2.315
$2.3911
1-Wochen-Bereich:
$2.24
$2.4999
52-Wochen-Spanne:
$1.21
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.335 | 156.01M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
430.61 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.97 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
781.73 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.08 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.80 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng
GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo
Buy Signal: What is the long term forecast for Galectin Therapeutics Inc stockTrade Analysis Report & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Targets Report: Whats next for Galectin Therapeutics Inc stockBond Market & Weekly Setup with High ROI Potential - baoquankhu1.vn
Dip Buying: Can Galectin Therapeutics Inc weather a recession2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Reacting to Market | Price at $2.37, Up 6.76%Stock Idea Sharing Hub - Cổng thông tin điện tử tỉnh Lào Cai
Earnings Risk: Is Galectin Therapeutics Inc stock a buy or sell2026 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Recap: What is the long term forecast for Galectin Therapeutics Inc stock2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Worth Holding | Price at $2.61, Down 2.25%Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Galectin Therapeutics Inc. (PHPN.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - marketbeat.com
Aug PostEarnings: Can Galectin Therapeutics Inc reach all time highs this year2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
What is HC Wainwright's Estimate for GALT Q1 Earnings? - MarketBeat
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - Stock Titan
Galectin Therapeutics Reports 2025 Financial Results, Advances Belapectin Program for MASH Cirrhosis, and Extends Cash Runway Through 2027 - Minichart
GALT SEC FilingsGalectin Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Galectin Therapeutics Reports 2025 Financial Results - National Today
Galectin Therapeutics Inc. (GALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Galectin Therapeutics 2025 Annual Report: Clinical Trials, Regulatory Challenges, and Biopharma Industry Risks - Minichart
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs - TradingView
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update - Yahoo Finance
NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT) - Stock Titan
Belapectin data and $30.8M 2025 loss at Galectin (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics 10-K: R&D cuts reduce cash burn; cash runway to Apr 2027 - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Galectin Therapeutics Files $200 Million Mixed Shelf - marketscreener.com
What makes Galectin Therapeutics Inc stock attractive today2026 Trade Ideas & Low Risk High Win Rate Picks - baoquankhu1.vn
Galectin Therapeutics Short Interest Rises 27% in March - National Today
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March - MarketBeat
Risk Recap: Is Galectin Therapeutics Inc in a bullish channel2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Retail Trends: Is Galectin Therapeutics Inc gaining market share2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
Galectin Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Aug Gainers: Does Galectin Therapeutics Inc stock have upside surprise potential2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Galectin Therapeutics (FRA:PHPN) PB Ratio : (As of Mar. 25, 2026) - gurufocus.com
Galectin Therapeutics Inc. (GALT) Stock forecasts - Yahoo Finance UK
Galectin Therapeutics (GALT) Projected to Post Earnings on Monday - MarketBeat
Wall Street Recap: What makes Galectin Therapeutics Inc stock attractive today - baoquankhu1.vn
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
1.36%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):